Eli Lilly (NY:LLY)

1,142.85 -7.00 (-0.61%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

99 100 Next >

Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031 ↗

August 01, 2026

And it will likely be the first company in the sector to get there.

Via The Motley Fool

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist? ↗

August 01, 2026

PBE surged 41% in one year but endured a 35% drawdown, while XLV's diversified approach delivered steadier gains with half the volatility.

Via The Motley Fool

Topics ETFs

Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit? ↗

August 01, 2026

FHLC holds 334 positions versus IYH's 100, yet both delivered similar five-year returns despite their structural differences.

Via The Motley Fool

Topics ETFs

Eli Lilly (NYSE:LLY): A Quality Dividend Stock with Sustainable Growth and Strong Fundamentals ↗

July 28, 2026

Via Chartmill

Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip? ↗

July 31, 2026

With the stock near a 5-year low, is it worth a look?

Via The Motley Fool

Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore. ↗

July 31, 2026

The global market for obesity drugs is soaring, yet Lilly has a dominant market share.

Via The Motley Fool

XLV vs. IHE: Which Healthcare ETF Is the Better Buy? ↗

July 31, 2026

IHE's pharma-focused portfolio delivered higher returns over the past year, while XLV offers a broader healthcare focus with a much lower expense ratio.

Via The Motley Fool

Topics ETFs Intellectual Property

Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels ↗

July 31, 2026

Wegovy and Zepbound makers Novo Nordisk and Eli Lilly faced pressure.

Via Investor's Business Daily

Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH? ↗

July 31, 2026

FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.

Via The Motley Fool

Topics ETFs

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗

July 30, 2026

There are other reasons to pay attention to Viking Therapeutics.

Via The Motley Fool

VHT vs. PBE: Which Health Care ETF Is the Better Buy? ↗

July 30, 2026

PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost...

Via The Motley Fool

Topics ETFs

Jim Cramer: Eli Lilly Is A 'Good Company,' But Doesn't 'Really Care For' This Quantum Stock ↗

July 30, 2026

CNBC's Mad Money Lightning Round: Cramer says Astera Labs (ALAB) is a buy, but doesn't care for Rigetti Computing (RGTI). Eli Lilly (LLY) is a classic own, don't trade. MakeMyTrip (MMYT) coverage...

Via Benzinga

Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗

July 29, 2026

But is that performance sustainable?

Via The Motley Fool

3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold ↗

July 29, 2026

They may profit from the rapidly growing GLP-1 market in very different ways.

Via The Motley Fool

State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio? ↗

July 29, 2026

FBT delivered 48.5% returns over one year but carries a 0.55% expense ratio and experiences greater volatility. XLV offers lower costs, with an 0.08% expense ratio, as well as broader diversification...

Via The Motley Fool

Topics ETFs

Forget Weight Loss Drugs: Here's Another Reason to Buy Eli Lilly Stock ↗

July 29, 2026

Lilly's pipeline is on track to pick up a handful of interesting new programs.

Via The Motley Fool

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients ↗

July 29, 2026

Will this pharma company become a new leader in the weight loss market?

Via The Motley Fool

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth ↗

July 29, 2026

Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.

Via The Motley Fool

Only 2 "Magnificent Seven" Stocks Are Beating the Market This Year. What's Going On? ↗

July 29, 2026

The market has hit new records this year, but it isn't the "Magnificent Seven" stocks that are leading the way.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet. ↗

July 29, 2026

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

Via The Motley Fool

Topics ETFs Government

4 Stocks That Can 4x Your Money in 4 Years ↗

July 28, 2026

Quadrupling your money in four years is an incredible rate of return.

Via The Motley Fool

Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs ↗

July 28, 2026

The company isn't resting on its laurels.

Via The Motley Fool

VUG vs. VTI: Which Vanguard ETF Is the Better Buy for Growth Stocks? ↗

July 28, 2026

Can growth stocks maintain their momentum, or is it time to diversify?

Via The Motley Fool

Topics Artificial Intelligence ETFs

Where Will Novo Nordisk Stock Be in 3 Years? ↗

July 28, 2026

Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while.

Via The Motley Fool

Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees ↗

July 28, 2026

VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors.

Via The Motley Fool

Topics ETFs

SCHD vs. VIG: Which Dividend ETF Could Build More Wealth Over 20 Years? ↗

July 28, 2026

The Schwab U.S. Dividend Equity ETF has the superior selection strategy, while the Vanguard Dividend Appreciation ETF has a bigger growth and tech tilt.

Via The Motley Fool

Topics ETFs Stocks

XLV vs IYH: Which Healthcare ETF Wins on Cost and Yield? ↗

July 27, 2026

State Street's fund charges just 0.08% annually versus 0.38% for iShares, but the broader portfolio offers 100 holdings versus 60.

Via The Motley Fool

Topics ETFs

XLV vs FHLC: Which Healthcare ETF Fits Your Portfolio? ↗

July 27, 2026

State Street's concentrated 60-stock approach outpaced Fidelity's broader 365-holding fund over five years, though both charge identical 0.08% fees.

Via The Motley Fool

Topics ETFs

3 Quality Compounders to Own for Decades

July 27, 2026

A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits...

Via StockStory

Pharmaceuticals Stocks Q1 In Review: Ocular Therapeutix (NASDAQ:OCUL) Vs Peers

July 26, 2026

Let’s dig into the relative performance of Ocular Therapeutix (NASDAQ:OCUL) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings season....

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.